

Morten Hyer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1729209/morten-hoyer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

6,396
citations

39
h-index

76
g-index

158
ext. papers

7,536
ext. citations

3
avg, IF

5.49
L-index

#	Paper	IF	Citations
145	Spot-scanning proton therapy for targets with adjacent cardiac implantable electronic devices - Strategies for breast and head & neck cancer.. <i>Physics and Imaging in Radiation Oncology</i> , 2022 , 21, 66-71 ^{3,1}		
144	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group.. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 34, 1-6	4.6	1
143	Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. <i>Acta Oncologica</i> , 2021 , 1-5	3.2	0
142	Proton therapy for early breast cancer patients in the DBCG proton trial: planning, adaptation, and clinical experience from the first 43 patients. <i>Acta Oncologica</i> , 2021 , 1-8	3.2	2
141	Response to: Comments on "Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma" by Toussaint, et al.: Prior similar field arrangement work and a need for variable RBE Use <i>Radiotherapy and Oncology</i> , 2021 , 158, 330-331	5.3	
140	Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021 , 11, 695647	5.3	
139	Risk of Cardiac Implantable Electronic Device Malfunctioning During Pencil Beam Proton Scanning in an In Vitro Setting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 186-195	4	1
138	A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. <i>Acta Oncologica</i> , 2021 , 1-6	3.2	0
137	Real-time dose-guidance in radiotherapy: Proof of principle. <i>Radiotherapy and Oncology</i> , 2021 , 164, 175-182	3.2	0
136	Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?. <i>Radiotherapy and Oncology</i> , 2021 , 163, 177-184	5.3	6
135	Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [F]FDGal PET/CT. <i>Radiation Oncology</i> , 2021 , 16, 192	4.2	
134	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020 , 148, 157-166	5.3	113
133	Isotoxic dose prescription level strategies for stereotactic liver radiotherapy: the price of dose uniformity. <i>Acta Oncologica</i> , 2020 , 59, 558-564	3.2	4
132	Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 183-197	6.7	27
131	Simulated multileaf collimator tracking for stereotactic liver radiotherapy guided by kilovoltage intrafraction monitoring: Dosimetric gain and target overdose trends. <i>Radiotherapy and Oncology</i> , 2020 , 144, 93-100	5.3	8
130	Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model. <i>Scientific Reports</i> , 2020 , 10, 16223	4.9	3
129	A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients. <i>Acta Oncologica</i> , 2020 , 59, 1157-1163	3.2	2

128	Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma. <i>Radiotherapy and Oncology</i> , 2020 , 142, 140-146	5.3	10
127	Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours. <i>Radiotherapy and Oncology</i> , 2020 , 148, 1-7	5.3	12
126	Patient specific outcomes of charged particle therapy for hepatocellular carcinoma - A systematic review and quantitative analysis. <i>Radiotherapy and Oncology</i> , 2019 , 132, 127-134	5.3	12
125	Long-term cognitive dysfunction after radiation therapy for primary brain tumors. <i>Acta Oncologica</i> , 2019 , 58, 745-752	3.2	11
124	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019 , 37, 2607-2613	4	10
123	Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. <i>Acta Oncologica</i> , 2019 , 58, 1457-1462	3.2	8
122	Simulated real-time dose reconstruction for moving tumors in stereotactic liver radiotherapy. <i>Medical Physics</i> , 2019 , 46, 4738-4748	4.4	7
121	First clinical real-time motion-including tumor dose reconstruction during radiotherapy delivery. <i>Radiotherapy and Oncology</i> , 2019 , 139, 66-71	5.3	12
120	BIGART 2019 - adapting to the future. <i>Acta Oncologica</i> , 2019 , 58, 1323-1327	3.2	0
119	A Prospective Cohort Study of Gated Stereotactic Liver Radiation Therapy Using Continuous Internal Electromagnetic Motion Monitoring. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 366-375	4	28
118	Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. <i>Acta Oncologica</i> , 2018 , 57, 1084-1093	3.2	8
117	Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. <i>Radiotherapy and Oncology</i> , 2018 , 127, 88-95	5.3	11
116	Automatic online and real-time tumour motion monitoring during stereotactic liver treatments on a conventional linac by combined optical and sparse monoscopic imaging with kilovoltage x-rays (COSMIK). <i>Physics in Medicine and Biology</i> , 2018 , 63, 055012	3.8	11
115	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 20-26	1.6	5
114	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. <i>Technology in Cancer Research and Treatment</i> , 2018 , 17, 1533033818790217	2.7	39
113	Validation of fast motion-including dose reconstruction for proton scanning therapy in the liver. <i>Physics in Medicine and Biology</i> , 2018 , 63, 225021	3.8	1
112	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. <i>Radiotherapy and Oncology</i> , 2018 , 128, 26-36	5.3	60
111	Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy. <i>Physics in Medicine and Biology</i> , 2018 , 63, 145010	3.8	13

110	Metastasis directed therapy for liver and lung metastases from colorectal cancer-A population-based study. <i>International Journal of Cancer</i> , 2018 , 143, 3218-3226	7.5	14
109	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. <i>Radiotherapy and Oncology</i> , 2017 , 123, 182-188	5.3	41
108	Cone beam CT-based set-up strategies with and without rotational correction for stereotactic body radiation therapy in the liver. <i>Acta Oncologica</i> , 2017 , 56, 860-866	3.2	12
107	2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours. <i>Physics and Imaging in Radiation Oncology</i> , 2017 , 1, 28-33	3.1	4
106	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. <i>Cancer Treatment Reviews</i> , 2017 , 53, 25-37	14.4	115
105	Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. <i>Acta Oncologica</i> , 2017 , 56, 1514-1521	3.2	5
104	A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[F]fluoro-2-deoxy-d-galactose. <i>Acta Oncologica</i> , 2017 , 56, 1614-1620	3.2	5
103	Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer. <i>Acta Oncologica</i> , 2017 , 56, 1507-1513	3.2	14
102	Radiation Therapy for Liver Metastases: Clinical Data 2017 , 245-256		
101	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 457-463	1.6	4
100	Rethink radiotherapy - BIGART 2017. <i>Acta Oncologica</i> , 2017 , 56, 1341-1352	3.2	3
99	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017 , 124, 11-17	5.3	149
98	Simultaneous acquisition of 4D ultrasound and wireless electromagnetic tracking for in-vivo accuracy validation. <i>Current Directions in Biomedical Engineering</i> , 2017 , 3, 75-78	0.5	4
97	Re-irradiation with stereotactic body radiation therapy (SBRT). <i>Chinese Clinical Oncology</i> , 2017 , 6, S15	2.3	10
96	Fiducial marker guided stereotactic liver radiotherapy: Is a time delay between marker implantation and planning CT needed?. <i>Radiotherapy and Oncology</i> , 2016 , 121, 75-78	5.3	18
95	A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). <i>BMC Cancer</i> , 2016 , 16, 183	4.8	25
94	Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2016 , 55, 886-91	3.2	12
93	A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. <i>Acta Oncologica</i> , 2016 , 55, 1009-15	3.2	5

92	198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S143	8.9	2
91	The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2016 , 118, 154-9	5.3	37
90	Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016 , 119, 117-22	5.3	20
89	Time-Resolved Intrafraction Target Translations and Rotations During Stereotactic Liver Radiation Therapy: Implications for Marker-based Localization Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 802-9	4	34
88	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. <i>European Urology</i> , 2016 , 70, 684-691	10.2	48
87	Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , 2016 , 55, 598-603	3.2	15
86	Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. <i>Radiotherapy and Oncology</i> , 2015 , 114, 155-60	5.3	75
85	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2015 , 54, 1461-6	3.2	16
84	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. <i>Radiotherapy and Oncology</i> , 2015 , 116, 346-51	5.3	22
83	Survival and prognostic factors in patients treated with stereotactic radiotherapy for brain metastases. <i>Acta Oncologica</i> , 2015 , 54, 107-14	3.2	10
82	Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. <i>Acta Oncologica</i> , 2015 , 54, 1096-104	3.2	50
81	Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. <i>Acta Oncologica</i> , 2015 , 54, 1326-34	3.2	28
80	Respiratory gating based on internal electromagnetic motion monitoring during stereotactic liver radiation therapy: First results. <i>Acta Oncologica</i> , 2015 , 54, 1445-52	3.2	39
79	An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2015 , 54, 1335-42	3.2	7
78	An adaptive radiotherapy planning strategy for bladder cancer using deformation vector fields. <i>Radiotherapy and Oncology</i> , 2014 , 112, 371-5	5.3	12
77	Kilovoltage intrafraction motion monitoring and target dose reconstruction for stereotactic volumetric modulated arc therapy of tumors in the liver. <i>Radiotherapy and Oncology</i> , 2014 , 111, 424-30	5.3	40
76	Evaluation of an application for intensity-based deformable image registration and dose accumulation in radiotherapy. <i>Acta Oncologica</i> , 2014 , 53, 1329-36	3.2	21
75	Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014 , 111, 94-9	5.3	20

74	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. <i>Clinical Epidemiology</i> , 2014 , 6, 351-7	5.9	13
73	Fast motion-including dose error reconstruction for VMAT with and without MLC tracking. <i>Physics in Medicine and Biology</i> , 2014 , 59, 7279-96	3.8	19
72	A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014 , 53, 1321-8	3.2	23
71	Pathophysiology of late anorectal dysfunction following external beam radiotherapy for prostate cancer. <i>Acta Oncologica</i> , 2014 , 53, 1398-404	3.2	9
70	Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014 , 53, 997-1004	3.2	45
69	Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver. <i>Acta Oncologica</i> , 2013 , 52, 1437-44	3.2	36
68	Three-dimensional, time-resolved, intrafraction motion monitoring throughout stereotactic liver radiation therapy on a conventional linear accelerator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 190-7	4	51
67	Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: a dose accumulation comparison. <i>Radiotherapy and Oncology</i> , 2013 , 109, 457-62	5.3	48
66	Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. <i>Acta Oncologica</i> , 2013 , 52, 521-7	3.2	35
65	Time-resolved dose reconstruction by motion encoding of volumetric modulated arc therapy fields delivered with and without dynamic multi-leaf collimator tracking. <i>Acta Oncologica</i> , 2013 , 52, 1497-503	3.2	12
64	Time-resolved dose distributions to moving targets during volumetric modulated arc therapy with and without dynamic MLC tracking. <i>Medical Physics</i> , 2013 , 40, 111723	4.4	22
63	Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. <i>Clinical Epidemiology</i> , 2013 , 5, 327-34	5.9	17
62	Radiotherapy for liver metastases: a review of evidence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1047-57	4	145
61	On-line use of three-dimensional marker trajectory estimation from cone-beam computed tomography projections for precise setup in radiotherapy for targets with respiratory motion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e145-51	4	20
60	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. <i>Cancer</i> , 2012 , 118, 2476-85	6.4	180
59	An international survey on liver metastases radiotherapy. <i>Acta Oncologica</i> , 2012 , 51, 568-74	3.2	30
58	Radiation therapy for liver metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012 , 6, 97-102	2.6	11
57	Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. <i>Acta Oncologica</i> , 2011 , 50, 823-8	3.2	41

56	Robust automatic segmentation of multiple implanted cylindrical gold fiducial markers in cone-beam CT projections. <i>Medical Physics</i> , 2011 , 38, 6351-61	4.4	33
55	Faecal incontinence following radiotherapy for prostate cancer: a systematic review. <i>Radiotherapy and Oncology</i> , 2011 , 98, 145-53	5.3	37
54	Advances in radiotherapy: from 2D to 4D. <i>Cancer Imaging</i> , 2011 , 11 Spec No A, S147-52	5.6	2
53	Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009. <i>Clinical Epidemiology</i> , 2011 , 3 Suppl 1, 11-7	5.9	8
52	NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. <i>Acta Oncologica</i> , 2011 , 50, 518-27	3.2	26
51	Deformable image registration for contour propagation from CT to cone-beam CT scans in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2011 , 50, 918-25	3.2	97
50	Plan robustness in proton beam therapy of a childhood brain tumour. <i>Acta Oncologica</i> , 2011 , 50, 791-6	3.2	9
49	Clinical validation of a 4D-CT based method for lung ventilation measurement in phantoms and patients. <i>Acta Oncologica</i> , 2011 , 50, 897-907	3.2	14
48	Stereotactic body radiotherapy for unresectable cholangiocarcinoma. <i>Radiotherapy and Oncology</i> , 2010 , 94, 47-52	5.3	122
47	Temporary sacral nerve stimulation for faecal incontinence following pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2010 , 97, 108-12	5.3	13
46	A comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2010 , 49, 1069-76	3.2	47
45	Inter- and intrafractional localisation errors in cone-beam CT guided stereotactic radiation therapy of tumours in the liver and lung. <i>Acta Oncologica</i> , 2010 , 49, 1177-83	3.2	50
44	A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. <i>Acta Oncologica</i> , 2010 , 49, 1109-15	3.2	40
43	Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. <i>Acta Oncologica</i> , 2010 , 49, 1023-32	3.2	69
42	Imaging of normal lung, liver and parotid gland function for radiotherapy. <i>Acta Oncologica</i> , 2010 , 49, 997-1011	3.2	21
41	Evaluation of adaptive radiotherapy of bladder cancer by image-based tumour control probability modelling. <i>Acta Oncologica</i> , 2010 , 49, 1045-51	3.2	18
40	Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 295-301	3.5	9
39	A method to individualize adaptive planning target volumes for deformable targets. <i>Physics in Medicine and Biology</i> , 2009 , 54, 7121-33	3.8	16

38	Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3290-6	2.2	651
37	Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3330-7	2.2	222
36	Half body irradiation of patients with multiple bone metastases: a phase II trial. <i>Acta Oncologica</i> , 2009 , 48, 556-61	3.2	23
35	The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. <i>Acta Oncologica</i> , 2009 , 48, 238-44	3.2	31
34	Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2009 , 93, 402-7	5.3	84
33	Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. <i>Lancet, The</i> , 2009 , 373, 301-8	4.0	637
32	Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. <i>Radiotherapy and Oncology</i> , 2008 , 88, 359-67	5.3	108
31	Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging. <i>Acta Oncologica</i> , 2008 , 47, 1351-7	3.2	14
30	The normal tissue sparing potential of adaptive strategies in radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2008 , 47, 1382-9	3.2	17
29	FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. <i>Scandinavian Journal of Surgery</i> , 2007 , 96, 209-13	3.1	17
28	Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath urethral catheter technique. <i>Radiotherapy and Oncology</i> , 2007 , 83, 25-30	5.3	7
27	Residual set-up errors and margins in on-line image-guided prostate localization in radiotherapy. <i>Radiotherapy and Oncology</i> , 2007 , 85, 201-6	5.3	37
26	Radical radiotherapy for urinary bladder cancer: treatment outcomes. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 269-79	3.5	15
25	Phase II study on stereotactic body radiotherapy of colorectal metastases. <i>Acta Oncologica</i> , 2006 , 45, 823-30	3.2	320
24	Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. <i>Acta Oncologica</i> , 2006 , 45, 787-95	3.2	192
23	Internal movement, set-up accuracy and margins for stereotactic body radiotherapy using a stereotactic body frame. <i>Acta Oncologica</i> , 2006 , 45, 948-52	3.2	26
22	Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. <i>Acta Oncologica</i> , 2006 , 45, 973-7	3.2	7
21	Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?. <i>Acta Oncologica</i> , 2006 , 45, 818-22	3.2	31

20	Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2005 , 74, 203-10	5.3	50
19	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2005 , 76, 48-53	5.3	246
18	Comparison of two dose calculation methods applied to extracranial stereotactic radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 2005 , 77, 96-8	5.3	15
17	Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2004 , 43, 749-57	3.2	19
16	Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 436-44	4	93
15	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2004 , 72, 139-45	5.3	50
14	Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 519-25	4	16
13	Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. <i>Gynecologic Oncology</i> , 2001 , 81, 58-62	4.9	46
12	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. <i>Leukemia Research</i> , 2000 , 24, 999-1008	2.7	1
11	Dynamic cell cycle kinetics of normal CD34+ cells and CD38+/- subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood. <i>British Journal of Haematology</i> , 1999 , 105, 1002-13	4.5	7
10	The effect of castration on tumour growth rate and cell kinetics in hormone-sensitive and hormone-insensitive rat prostatic adenomas. <i>Prostate Cancer and Prostatic Diseases</i> , 1999 , 2, S29	6.2	
9	The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. <i>Radiotherapy and Oncology</i> , 1999 , 50, 13-23	5.3	130
8	Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. <i>Cytometry</i> , 1998 , 32, 28-36		40
7	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. <i>Prostate</i> , 1998 , 36, 244-9	4.2	21
6	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 1998 , 46, 147-55	5.3	28
5	Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , 1997 , 43, 47-51	5.3	109
4	The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 35, 701-8	4	127
3	MIB-1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. <i>Histopathology</i> , 1996 , 28, 437-44	7.3	16

- 2 Influence of sampling time on assessment of potential doubling time. *Cytometry*, **1994**, 16, 144-51 13
- 1 Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. *Radiotherapy and Oncology*, **1993**, 27, 131-9 53 80